Sarilumab is a monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs. Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6.
- Mechanism
- Curator reviewed · 1 reference
Sarilumab is a human recombinant IgG1 antibody that binds to both forms of interleukin 6 receptors (IL-6R), thus inhibiting IL-6-mediated signaling. IL-6 is a pleiotropic cytokine that activates immune cells (T and B cells) and hepatocytes for the release of acute phase proteins like CRP, serum amyloid A and fibrinogen, which are biomarkers of rheumatoid arthritis (RA) activity. IL-6 is also found in synovial fluid and plays a major role in the pathological inflammation and joint destruction features of RA. Thus, it is used for the treatment of RA due to its ability to inhibit intra-articular and systemic IL-6 signaling.
- Primary indication
- Sarilumab is indicated for the treatment of following conditions: moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more diseasemodifying antirheumatic drugs (DMARDs) - polymyalgia...Curator reviewed · 7 structured indications
- Formula / weight
- C6388H9918N1718O1998S44 · 150000.0 Da (143900 Da in absence of N-glycosylation in heavy chains (Asn296))
- First approval
- Canada, 2017 · United States, 2017 · European Union, 2020
- Also known as
- REGN88 · SAR153191
- Brand names
Resolves to
What you can answer from here — as of April 06, 2025
Which drugs share a target with Sarilumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account